Xu B, Li S, Kang B, Fan S, Chen C, Li W
Mol Biol Rep. 2023; 50(11):9637-9647.
PMID: 37819499
DOI: 10.1007/s11033-023-08836-0.
Li J, Florez J
Drugs. 2022; 82(13):1389-1401.
PMID: 36123514
PMC: 9531144.
DOI: 10.1007/s40265-022-01774-4.
Klen J, Dolzan V
Int J Mol Sci. 2021; 22(18).
PMID: 34575958
PMC: 8466905.
DOI: 10.3390/ijms22189800.
Iancu D, Ashton E
Genes (Basel). 2020; 11(3).
PMID: 32150856
PMC: 7140864.
DOI: 10.3390/genes11030277.
Yu L, Wu M, Hou P, Zhang H
BMC Nephrol. 2020; 21(1):69.
PMID: 32111189
PMC: 7047355.
DOI: 10.1186/s12882-020-01725-9.
A novel compound heterozygous mutation in SLC5A2 contributes to familial renal glucosuria in a Chinese family, and a review of the relevant literature.
Li S, Yang Y, Huang L, Kong M, Yang Z
Mol Med Rep. 2019; 19(5):4364-4376.
PMID: 30942416
PMC: 6472135.
DOI: 10.3892/mmr.2019.10110.
A recurrent deletion in the SLC5A2 gene including the intron 7 branch site responsible for familial renal glucosuria.
Zhao X, Cui L, Lang Y, Liu T, Lu J, Wang C
Sci Rep. 2016; 6:33920.
PMID: 27666404
PMC: 5036194.
DOI: 10.1038/srep33920.
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents.
Dawed A, Zhou K, Pearson E
Pharmgenomics Pers Med. 2016; 9:17-29.
PMID: 27103840
PMC: 4827904.
DOI: 10.2147/PGPM.S84854.
Influence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over Time.
Ottosson-Laakso E, Tuomi T, Forsen B, Gullstrom M, Groop P, Groop L
PLoS One. 2016; 11(1):e0146114.
PMID: 26735923
PMC: 4703216.
DOI: 10.1371/journal.pone.0146114.
Hypouricaemia and hyperuricosuria in familial renal glucosuria.
Aires I, Santos A, Pratas J, Nolasco F, Calado J
Clin Kidney J. 2015; 6(5):523-5.
PMID: 26064518
PMC: 4438413.
DOI: 10.1093/ckj/sft100.
Clinical and genetic analysis in a patient with primary renal glucosuria: Identification of a novel mutation in the gene.
Lee Y
Exp Ther Med. 2013; 6(6):1532-1534.
PMID: 24255686
PMC: 3829744.
DOI: 10.3892/etm.2013.1326.
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?.
Majumdar S, Inzucchi S
Endocrine. 2013; 44(1):47-58.
PMID: 23354728
DOI: 10.1007/s12020-013-9884-3.
Familial renal glucosuria: a clinicogenetic study of 23 additional cases.
Lee H, Han K, Park H, Shin J, Kim C, Namgung M
Pediatr Nephrol. 2012; 27(7):1091-5.
PMID: 22314875
DOI: 10.1007/s00467-012-2109-9.
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
Ferrannini E, Solini A
Nat Rev Endocrinol. 2012; 8(8):495-502.
PMID: 22310849
DOI: 10.1038/nrendo.2011.243.
Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.
Maurer T, Ghosh A, Haddish-Berhane N, Sawant-Basak A, Boustany-Kari C, She L
AAPS J. 2011; 13(4):576-84.
PMID: 21870203
PMC: 3231856.
DOI: 10.1208/s12248-011-9297-2.
Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients.
Yu L, Lv J, Zhou X, Zhu L, Hou P, Zhang H
Hum Genet. 2010; 129(3):335-44.
PMID: 21165652
DOI: 10.1007/s00439-010-0927-z.
SGLT2 mediates glucose reabsorption in the early proximal tubule.
Vallon V, Platt K, Cunard R, Schroth J, Whaley J, Thomson S
J Am Soc Nephrol. 2010; 22(1):104-12.
PMID: 20616166
PMC: 3014039.
DOI: 10.1681/ASN.2010030246.
SGLT2 inhibition--a novel strategy for diabetes treatment.
Chao E, Henry R
Nat Rev Drug Discov. 2010; 9(7):551-9.
PMID: 20508640
DOI: 10.1038/nrd3180.
Inherited epithelial transporter disorders--an overview.
Bergeron M, Simonin A, Burzle M, Hediger M
J Inherit Metab Dis. 2008; 31(2):178-87.
PMID: 18415698
DOI: 10.1007/s10545-008-0861-6.